SARS‐CoV‐2 research using human pluripotent stem cells and organoids

Sayaka Deguchi; Ángel Serrano‐aroca; Murtaza M. Tambuwala; Bruce D. Uhal; Adam M. Brufsky; Kazuo Takayama

doi:10.1002/sctm.21-0183

SARS‐CoV‐2 research using human pluripotent stem cells and organoids

Sayaka Deguchi, Ángel Serrano‐aroca, Murtaza M. Tambuwala, Bruce D. Uhal, Adam M. Brufsky, Kazuo Takayama

School of Pharm. & Pharmaceut. Sc.

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

51 Downloads (Pure)

Abstract

Experimental cell models are indispensable for clarifying the pathophysiology of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and for developing therapeutic agents. To recapitulate the symptoms and drug response of COVID-19 patients in vitro, SARS-CoV-2 studies using physiologically relevant human embryonic stem (ES)/induced pluripotent stem (iPS) cell-derived somatic cells and organoids are ongoing. These cells and organoids have been used to show that SARS-CoV-2 can infect and damage various organs including the lung, heart, brain, intestinal tract, kidney, and pancreas. They are also being used to develop COVID-19 therapeutic agents, including evaluation of their antiviral efficacy and safety. The relationship between COVID-19 aggravation and human genetic backgrounds has been investigated using genetically modified ES/iPS cells and patient-derived iPS cells. This review summarizes the latest results and issues of SARS-CoV-2 research using human ES/iPS cell-derived somatic cells and organoids.

Original language	English
Pages (from-to)	1491-1499
Number of pages	9
Journal	STEM CELLS Translational Medicine
Volume	10
Issue number	11
DOIs	https://doi.org/10.1002/sctm.21-0183
Publication status	Published (in print/issue) - 24 Jul 2021

Bibliographical note

Funding Information:
We thank Dr. Peter Karagiannis (Kyoto University) for critical reading of the manuscript and Dr. Misaki Ouchida (Kyoto University) for drawing the graphical abstract.

Publisher Copyright:
© 2021 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals LLC on behalf of AlphaMed Press.

Keywords

COVID-19
SARS-CoV-2
human ES cells
human iPS cells
organoids

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/sctm.21-0183Licence: CC BY-NC

sctm.21-0183 (1)Final published version, 456 KB

https://pubmed.ncbi.nlm.nih.gov/34302450/

Cite this

@article{00f0b89550a741baa1c2faa477cd9d68,

title = "SARS‐CoV‐2 research using human pluripotent stem cells and organoids",

abstract = "Experimental cell models are indispensable for clarifying the pathophysiology of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and for developing therapeutic agents. To recapitulate the symptoms and drug response of COVID-19 patients in vitro, SARS-CoV-2 studies using physiologically relevant human embryonic stem (ES)/induced pluripotent stem (iPS) cell-derived somatic cells and organoids are ongoing. These cells and organoids have been used to show that SARS-CoV-2 can infect and damage various organs including the lung, heart, brain, intestinal tract, kidney, and pancreas. They are also being used to develop COVID-19 therapeutic agents, including evaluation of their antiviral efficacy and safety. The relationship between COVID-19 aggravation and human genetic backgrounds has been investigated using genetically modified ES/iPS cells and patient-derived iPS cells. This review summarizes the latest results and issues of SARS-CoV-2 research using human ES/iPS cell-derived somatic cells and organoids.",

keywords = "COVID-19, SARS-CoV-2, human ES cells, human iPS cells, organoids",

author = "Sayaka Deguchi and {\'A}ngel Serrano‐aroca and Tambuwala, {Murtaza M.} and Uhal, {Bruce D.} and Brufsky, {Adam M.} and Kazuo Takayama",

note = "Funding Information: We thank Dr. Peter Karagiannis (Kyoto University) for critical reading of the manuscript and Dr. Misaki Ouchida (Kyoto University) for drawing the graphical abstract. Publisher Copyright: {\textcopyright} 2021 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals LLC on behalf of AlphaMed Press.",

year = "2021",

month = jul,

day = "24",

doi = "10.1002/sctm.21-0183",

language = "English",

volume = "10",

pages = "1491--1499",

journal = "STEM CELLS Translational Medicine",

issn = "2157-6564",

publisher = "John Wiley and Sons Ltd",

number = "11",

}

TY - JOUR

T1 - SARS‐CoV‐2 research using human pluripotent stem cells and organoids

AU - Deguchi, Sayaka

AU - Serrano‐aroca, Ángel

AU - Tambuwala, Murtaza M.

AU - Uhal, Bruce D.

AU - Brufsky, Adam M.

AU - Takayama, Kazuo

N1 - Funding Information: We thank Dr. Peter Karagiannis (Kyoto University) for critical reading of the manuscript and Dr. Misaki Ouchida (Kyoto University) for drawing the graphical abstract. Publisher Copyright: © 2021 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals LLC on behalf of AlphaMed Press.

PY - 2021/7/24

Y1 - 2021/7/24

N2 - Experimental cell models are indispensable for clarifying the pathophysiology of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and for developing therapeutic agents. To recapitulate the symptoms and drug response of COVID-19 patients in vitro, SARS-CoV-2 studies using physiologically relevant human embryonic stem (ES)/induced pluripotent stem (iPS) cell-derived somatic cells and organoids are ongoing. These cells and organoids have been used to show that SARS-CoV-2 can infect and damage various organs including the lung, heart, brain, intestinal tract, kidney, and pancreas. They are also being used to develop COVID-19 therapeutic agents, including evaluation of their antiviral efficacy and safety. The relationship between COVID-19 aggravation and human genetic backgrounds has been investigated using genetically modified ES/iPS cells and patient-derived iPS cells. This review summarizes the latest results and issues of SARS-CoV-2 research using human ES/iPS cell-derived somatic cells and organoids.

AB - Experimental cell models are indispensable for clarifying the pathophysiology of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and for developing therapeutic agents. To recapitulate the symptoms and drug response of COVID-19 patients in vitro, SARS-CoV-2 studies using physiologically relevant human embryonic stem (ES)/induced pluripotent stem (iPS) cell-derived somatic cells and organoids are ongoing. These cells and organoids have been used to show that SARS-CoV-2 can infect and damage various organs including the lung, heart, brain, intestinal tract, kidney, and pancreas. They are also being used to develop COVID-19 therapeutic agents, including evaluation of their antiviral efficacy and safety. The relationship between COVID-19 aggravation and human genetic backgrounds has been investigated using genetically modified ES/iPS cells and patient-derived iPS cells. This review summarizes the latest results and issues of SARS-CoV-2 research using human ES/iPS cell-derived somatic cells and organoids.

KW - COVID-19

KW - SARS-CoV-2

KW - human ES cells

KW - human iPS cells

KW - organoids

UR - https://onlinelibrary.wiley.com/doi/10.1002/sctm.21-0183

UR - http://www.scopus.com/inward/record.url?scp=85111403074&partnerID=8YFLogxK

U2 - 10.1002/sctm.21-0183

DO - 10.1002/sctm.21-0183

M3 - Article

C2 - 34302450

SN - 2157-6564

VL - 10

SP - 1491

EP - 1499

JO - STEM CELLS Translational Medicine

JF - STEM CELLS Translational Medicine

IS - 11

ER -

SARS‐CoV‐2 research using human pluripotent stem cells and organoids

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this